Breye Therapeutics ApS: Financial statements 2022
CVR: 40279865
Source: annual report 2022, Danish Business Authority
01/04/2021 – 31/03/2022
Breye Therapeutics ApS (CVR 40279865) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -673,849 and a net result of DKK -780,005 compared with DKK -289,668 the year before. Equity in the 2022 report amounted to DKK -751,744. The company had 1 employee in the financial year.
- Gross Profit
- DKK -673,849
- Profit/Loss
- DKK -780,005
- Equity
- DKK -751,744
- Total Assets
- DKK 18,745,891
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -674 t. | -780 t. | -752 t. | 1 |
| 2021 | - | -68 t. | -290 t. | 28 t. | 1 |
Official annual report
Keep an eye on Breye Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 5, 2022, Gabriela Burian has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, EY Godkendt Revisionspartnerselskab has been appointed auditor of Breye Therapeutics ApS.
As of November 4, 2022, EMIT P/S has stepped down as auditor of Breye Therapeutics ApS.
As of November 4, 2022, Jørgen Søberg Petersen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Ulrik Mouritzen has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Jimmy Arnold V Van Heusden has joined the board of directors of Breye Therapeutics ApS.
As of November 4, 2022, Carl Johan Kördel has joined the board of directors of Breye Therapeutics ApS.
On November 4, 2022, the company changed its name from Ciana Therapeutics ApS to Breye Therapeutics ApS.
About Breye Therapeutics ApS
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ciana Therapeutics ApS and Visus Therapeutics ApS. The management consists of Ulrik Mouritzen. The board consists of Jimmy Arnold V Van Heusden (chair), Carl Johan Kördel, Chiara Rossana Maria Liberati and Gabriela Burian. The company's owners include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S. The company has 3 employees (2026). In 2026, the company reported a gross profit of DKK -7,655,438 and a net result of DKK -85,575,302 compared with DKK -89,139,846 the year before. Equity in the 2026 report amounted to DKK -126,213,092.